Dear reader, online ads enable us to deliver the journalism you value. Please support us by taking a moment to turn off Adblock on Dawn.com.

Email


Your Name:


Recipient Email:


A man walks past the logo of Swiss drugmaker Novartis AG in front of a plant in Basel October 25, 2011. - REUTERS PHOTO

ZURICH | Mon Oct 1, 2012 - Swiss drugmaker Novartis said on Monday the European Commission had approved its Seebri Breezhaler as a once-daily treatment for adult patients with chronic obstructive pulmonary disease, more commonly known as smoker's cough, in the European Union.

Trials showed that the treatment significantly improved lung function over the first four hours after morning dosing when compared to placebo, and that this benefit was sustained for 24 hours over a 52-week period, Novartis said.

The group said the treatment will be available to physicians and patients in some European Union markets by year end.

Deutsche Bank has estimated peak sales for Seebri Breezhaler at some $500 million.

 

 

DAWN_VIDEO - /1029551/DAWN-RM-1x1

LARGE_RECTANGLE_BOTTOM - /1029551/Dawn_ASA_Unit_670x280


Comments (0) Closed